Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death‐1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non‐s...
| Glavni autori: | , , , , , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
Wiley
2019-12-01
|
| Serija: | CPT: Pharmacometrics & Systems Pharmacology |
| Online pristup: | https://doi.org/10.1002/psp4.12476 |